Inhibition of lipid peroxidation in low-density lipoprotein by the flavonoid myrigalone B and ascorbic acid

Biochemical Pharmacology

Volumn 51, Issue 12, 1996, Pages 1719-1725

  Mathiesen, Liv ^a   Wang, Siri ^a   Halvorsen, Bente ^a   Malterud, Karl E ^a   Sund, Reidar B ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

ascorbic acid; flavonoids; lipid peroxidation; myrigalone B; oxidized LDL

Indexed keywords

ASCORBIC ACID; COPPER ION; ESTER C; FLAVONOID; LOW DENSITY LIPOPROTEIN; MYRIGALONE B; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; LIPID PEROXIDATION; PRIORITY JOURNAL;

EID: 0029893463     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00107-4     Document Type: Article

References (39)

1. Ross R, The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-803, 1993.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC and Witztum JL, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
3. Esterbauer H, Gebicki J, Puhl H and Jürgens G, The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 13: 341-390, 1992.
4. Steinberg D, Antioxidant vitamins and coronary heart disease. N Engl J Med 328: 1487-1489, 1993.
5. Parthasarathy S, Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77: 641-643, 1986.
6. Björkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L and Henriksson P, The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 11: 15-22, 1991.
7. Nègre-Salvayre A and Salvayre R, Quercetin prevents the cytotoxicity of oxidized LDL on lymphoid cell lines. Free Rad Biol Med 12: 101-106, 1992.
8. Mangiapane H, Thomson J, Salter A, Brown S, Bell GD and White DA, The inhibition of the oxidation of low density lipoprotein by (+)-catechin, a naturally occurring flavonoid. Biochem Pharmacol 43: 445-450, 1992.
9. Jessup W, Rankin SM, De Whalley CV, Hoult JRS, Scott J and Leake DS, α-Tocopherol consumption during low-density-lipoprotein oxidation. Biochem J 265: 399-405, 1990.
10. De Whalley CV, Hoult JRS, Jessup W and Leake DS, Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem Pharmacol 39: 1743-1750, 1990.
11. Frankel EN, Kanner J, German JB, Parks E and Kinsella JE, Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 341: 454-457, 1993.
12. Fuhrman B, Lavy A and Aviram M, Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 61: 549-554, 1995.
13. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB and Kromhout D, Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007-1011, 1993.
14. Uyar T, Malterud KE and Anthonsen T, Two new dihydrochalcones from Myrica gale. Phytochemistry 17: 2011-2013, 1978.
15. Malterud KE, C-methylated dihydrochalcones from Myrica gale fruit exudate. Acta Pharm Nord 4: 65-68, 1992.
16. Malterud KE, Diep HO and Sund RB, C-Methylated dihydrochalcones from Myrica gale L.: Effects as antioxidants and as scavengers of 1,1-diphenyl-2-picrylhydrazyl. Pharmacol Toxicol 78: 111-116, 1996.
17. Mathiesen L, Malterud KE and Sund RB: Antioxidant activity of fruit exudate and C-methylated dihydrochalcones from Myrica gale L. Planta Med 61: 515-518, 1995.
18. Mathiesen L, Malterud KE, Nenseter MS and Sund RB: Inhibition of low density lipoprotein oxidation by myrigalone B, a naturally occurring flavonoid. Pharmacol Toxicol 78: 143-146, 1996.
19. Frei B, Stocker R and Ames BN, Antioxidant defences and lipid peroxidation in human blood plasma. Proc Nad Acad Sci USA 85: 9748-9752, 1988.
20. Esterbauer H, Striegl G, Puhl H, Oberreither S, Rotheneder M, El-Saadani M and Jürgens G, The role of vitamin E and carotenoids in preventing oxidation of low density lipoproteins. Ann NY Acad Sci 570: 254-267, 1989.
21. Retsky KL, Freeman MW and Frei B, Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti-rather than prooxidant activity of vitamin C in the presence of transition metal ions. J Biol Chem 268: 1304-1309, 1993.
22. Niki E, Interaction of ascorbate and α-tocopherol. Ann NY Acad Sci 498: 186-198, 1987.
23. Kagan VE, Serbinova EA, Forte T, Scita G and Packer L, Recycling of vitamin E in human low density lipoprotein. J Lipid Res 33: 385-397, 1992.
24. Nègre-Salvayre A, Affany A, Hariron C and Salvayre R, Additional antilipoperoxidant activities of alpha-tocopherol and ascorbic acid on membrane-like systems are potentiated by rutin. Pharmacology 42: 262-272, 1991.
25. Nègre-Salvayre A, Mabile L, Delchambre J and Salvayre R, α-Tocopherol, ascorbic acid, and rutin inhibit synergistically the copper-promoted LDL oxidation and the cytotoxicity of oxidized LDL to cultured endothelial cells. Biol Trace Element Res 47: 81-91, 1995.
26. Bush MJ and Verlangieri AJ, An acute study on the relative gastro-intestinal absorption of a novel form of calcium ascorbate. Res Comm Chem Pathol Pharmacol 57: 137-140, 1987.
27. ® vs. L-ascorbic acid. Report. Meridan Valley Clinical Laboratory, 1987.
28. Havel RJ, Eder HA and Bragdon JH, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
29. Noble RP, Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9: 693-700, 1968.
30. Rumsey SC, Galeano NF, Arad Y and Deckelbaum RJ, Cryopreservaton with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res 33: 1551-1561, 1992.
31. Bradford M, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 72: 248-254, 1976.
32. Esterbauer H, Striegl G, Puhl H and Rotheneder M, Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Comms 6: 67-75, 1989.
33. Jialal I, Vega GL and Grundy SM, Physiological levels of ascorbate inhibit the oxidative modification of low density lipoprotein. Atherosclerosis 82: 185-191, 1990.
34. Kuzuya M, Yamada K, Hayashi T, Funaki C, Naito M, Asai K and Kuzuya F, Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein. Biochim Biophys Acta 1123: 334-341, 1992.
35. Gerhartz W, ed. Ullmann's encyclopedia of industrial chemistry. 5. ed. Verlag Chemie, Weinheim, 1987.
36. Wang S, Schram IM and Sund RB, Determination of ascorbic acid in plasma: method and stability studies. Eur J Pharm Sci 3: 231-239, 1995.
37. Nenseter MS, Halvorsen B, Rosvold Ø, Rustan AC and Drevon CA, Paracetamol inhibits copper-catalyzed, azo compound-and mononuclear cell-mediated oxidative modification of low density lipoprotein. Arterioscler Thromb Vasc Biol 15: 1338-1344, 1995.
38. Suzukawa M, Ishikawa T, Yoshida H and Nakamura H, Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification. J Am Coll Nutr 14: 46-52, 1995.
39. Bors W, Michel C and Schikora S, Interaction of flavonoids with ascorbate and determination of their univalent redox potentials: A pulse radiolysis study. Free Rad Biol Med 19: 45-52, 1995.